SCHEMBL24157241

SCHEMBL24157241

CCC1Nc2ccc(Br)c(C)c2NC1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAT2 Q10469 1/20 0.34
▸ BRD4 O60885 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ TP53 P04637 5/20 0.32
▸ MAPT P10636 5/20 0.32
▸ POLB P06746 2/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ PDE3B Q13370 1/20 0.31
▸ PDE3A Q14432 1/20 0.31
▸ GAA P10253 2/20 0.30
▸ SMN1; SMN2 Q16637 2/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ NPC1 O15118 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30212699 1.00 MGAT2 (0.34) MGAT2BRD4CREBBPTP53MAPT
SCHEMBL30212563 0.84 MGAT2 (0.34) MGAT2BRD4CREBBPMAPTKDM4E
SCHEMBL24157270 0.84 PGR (0.34) MGAT2BRD4CREBBPTP53MAPT
SCHEMBL24157277 0.84 MGAT2 (0.34) MGAT2BRD4CREBBPMAPTKDM4E
SCHEMBL24157395 0.80 BRPF1 (0.47) BRD4CREBBPTP53MAPTPOLB
SCHEMBL30212596 0.80 BRPF1 (0.47) BRD4CREBBPTP53MAPTPOLB
SCHEMBL4860943 0.72 TP53 (0.44) MGAT2BRD4TP53MAPTPOLB
SCHEMBL4869296 0.72 TP53 (0.44) MGAT2TP53MAPTPOLBKDM4E
SCHEMBL25316346 0.72 TP53 (0.44) MGAT2TP53MAPTPOLBKDM4E
SCHEMBL28821831 0.72 TP53 (0.44) MGAT2BRD4TP53MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795158-B2 Chemical compounds ASTRAZENECA AB (SE) 2023-10-24 — — US disclosed
US-11795158-B2 Chemical compounds ASTRAZENECA AB (SE) 2023-10-24 — — US disclosed
WO-2023118085-A1 METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS ASTRAZENECA AB (SE) 2023-06-29 — — WO disclosed
CN-115768760-A Quinoxaline derivatives as anti-cancer agents 阿斯利康(瑞典)有限公司 2023-03-07 — — CN disclosed
WO-2021260092-A1 QUINOXALINE DERIVATIVES AS ANTI-CANCER DRUGS ASTRAZENECA AB (SE) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795158-B2 Chemical compounds CYP11B2, CYP11B1, CYP4B1 MGAT2 1714/4885BRD4 203/4885CREBBP 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback